

Minutes of the 278th (overall) and 146th meeting of the Authority under DPCO, 2013 held on 26.05.2026 at 12:30 PM.

The 278th meeting of the Authority (overall), which is the 146th meeting under the DPCO, 2013 was held on 26.05.2026 at 12:30 PM under the Chairmanship of Shri P. Krishnamurthy, Chairman, NPPA. The following Authority members were present during the meeting:

- (i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
- (ii) Shri Anand Kumar Pal, Chief Adviser (Cost), O/o Chief Adviser Cost, Department of Expenditure
- (iii) Dr. Rose Mary K. Abraham, Economic Advisor, Department of Economic Affairs

Shri Ranga Chandrashekar, Joint Drug Controller, CDSCO, Ministry of Health & Family Welfare .

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Shri Sanjay Kumar, Adviser (Cost)
- (ii) Ms. Priyanka Sachdeva, Joint Director (Pricing)
- (iii) Shri Mahaveer Saini, Joint Director (Pricing) – Additional Charge
- (iv) Ms. Yuvika Panwar, Deputy Director (Pricing) – Additional Charge
- (v) Shri Bhiva Ram Yadav, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of the Minutes of the 145th Meeting held on 30.04.2026.

1.1 The Authority confirmed the minutes of the meeting without any change.

2. Agenda item no. 2 – Action Taken Report (ATR) on decisions taken by NPPA in its 145th Meeting held on 30.04.2026.

2.1 Noted.

3. Agenda item no. 3 – Status of new drug application.

3.1 Noted.

4. Agenda item no. 4 – New Drug application for price fixation under Paragraph 5 and 15 of DPCO, 2013.

4.1 The Authority deliberated on 30 (Thirty) cases of retail price fixation of new drugs as presented in Agenda no. 4(1) to 4(30) falling under the purview of paragraph 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 30 (Thirty) new drugs under paragraph 5 and 15 of DPCO, 2013 as given in **Table 1 below:**

Table No. 1: Retail price fixation of new drugs

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	4(1)	Alginate Raft - Forming Oral Suspension	Each 5 ml contains: Sodium Alginate IP 250 mg Sodium Bicarbonate IP 133.5 mg Calcium Carbonate IP 80 mg	1 ml	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	0.90
2	4(2)	Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Liquid	Each 5 ml contains: Sodium Alginate IP 250 mg Sodium Bicarbonate IP 133.5 mg Calcium Carbonate IP 80 mg	1 ml	M/s Stedman Pharmaceuticals Pvt. Ltd.	0.95
3	4(3)	Atorvastatin and Fenofibrate Tablets	Each Film Coated Tablet Contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg Fenofibrate IP 160 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Wellness Ltd.	18.46
4	4(4)	Bilastine & Montelukast Tablets	Each Film Coated Bilayered Tablet Contains: Bilastine IP 40 mg Montelukast Sodium IP eq. to Montelukast 10 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	21.22
5	4(5)	Bisoprolol Fumarate and Amlodipine Tablets	Each film coated tablet contains: Bisoprolol Fumarate IP 5 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s Ipca Laboratories Ltd.	9.40
6	4(6)	Bisoprolol Fumarate and Amlodipine Tablets	Each Film Coated Tablet Contains: Bisoprolol Fumarate IP 2.5 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg	1 Tablet	M/s Swiss Garnier Life Sciences/ M/s Ipca Laboratories Ltd.	7.31
7	4(7)	Calcium, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5 Phosphate Tablets	Each Film Coated Tablet Contains: Calcium Carbonate IP 1250 mg Eq. to Elemental Calcium 500 mg Vitamin D3 IP 2000 IU Mecobalamin IP (Methylcobalamin) 1500 mcg L-Methylfolate Calcium 1 mg Pyridoxal - 5 - Phosphate 20 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharmaceutical Industries Ltd.	19.78
8	4(8)	Cefpodoxime and Potassium Clavulanate Oral Suspension	Each Combipack Contains: 1. Cefpodoxime & Potassium Clavulanate Oral Suspension Each 5 ml of constituted suspension contains: Cefpodoxime Proxetil IP Eq. to Cefpodoxime 50 mg	1 ml	M/s Malik Lifesciences Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	3.65

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
			Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 31.25 mg 2. Sterile Water for reconstitution (Pyrogen free) 30ml			
9	4(9)	Cefpodoxime and Potassium Clavulanate Oral Suspension	Each Combipack Contains: 1. Cefpodoxime & Potassium Clavulanate Oral Suspension Each 5 ml of constituted suspension contains: Cefpodoxime Proxetil IP Eq. to Cefpodoxime 100mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 62.50 mg 2. Sterile Water for reconstitution (Pyrogen free) 30ml	1 ml	M/s Malik Lifesciences Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	5.74
10	4(10)	Vitamin D3 Oral Solution	Each 5 ml Contains: Cholecalciferol IP 60000 IU (In Nano Droplet Form)	1 ml	M/s Tirupati Medicare Ltd./ M/s Intas Pharmaceuticals Ltd.	14.91 (Note-1)
11	4(11)	Cholecalciferol Oral Solution	Each 5ml contains: Cholecalciferol IP 60000 IU	1 ml	M/s Pharma Synth Formulations Ltd.	15.88
12	4(12)	Cilnidipine and Telmisartan Tablets	Each Film Coated Tablet Contains: Cilnidipine IP 20 mg Telmisartan IP 40 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Alkem Laboratories Ltd.	14.95
13	4(13)	Cilnidipine and Telmisartan Tablets	Each Film Coated Tablet Contains: Cilnidipine IP 10 mg Telmisartan IP 40 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd.	12.98
14	4(14)	Cilnidipine, Telmisartan & Metoprolol Succinate (ER) Tablets	Each Film Coated Tablet Contains: Metoprolol Succinate IP 23.75 mg Eq. to Metoprolol Tartrate 25 mg (As Extended Release) Cilnidipine IP 10 mg Telmisartan IP 40 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Wellness Ltd.	11.83
15	4(15)	Cilnidipine, Telmisartan & Metoprolol Succinate (ER) Tablets	Each Film Coated Tablet Contains: Metoprolol Succinate IP 47.50 mg Eq. to Metoprolol Tartrate 50 mg (As Extended Release) Cilnidipine IP 10 mg Telmisartan IP 40 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Wellness Ltd.	14.80
16	4(16)	Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate,	Composition: Diclofenac Diethylamine IP 1.16% w/w (eq. to Diclofenac Sodium 1% w/w) Linseed Oil BP 3% w/w Methyl Salicylate IP 10%	1 gm	M/s Theon Pharmaceuticals Ltd./ M/s Jagsonpal Pharmaceuticals Ltd.	3.31

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		Capsaicin & Menthol Gel	w/w Capsaicin USP 0.025% w/w Menthol IP 5% w/w Benzyl Alcohol IP 1% w/w (Preservative)			
17	4(17)	Diclofenac Potassium, Paracetamol & Serratiopeptidase Tablets	Each film coated tablet contains: Diclofenac Potassium BP 50 mg Paracetamol IP 325 mg Serratiopeptidase IP 10 mg (As enteric coated granules Eq. 20000 Serratiopeptidase Units)	1 Tablet	M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd.	10.07
18	4(18)	Dicyclomine Hydrochloride & Diclofenac Sodium Injection	Each ml contains Dicyclomine Hydrochloride IP 10 mg Diclofenac Sodium IP 25 mg Benzyl Alcohol IP 4% v/v (as preservative)	1 ml	M/s Nichepharm Lifesciences Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	10.05
19	4(19)	Dicyclomine Hydrochloride & Diclofenac Sodium Injection	Each ml contains: Dicyclomine Hydrochloride IP 20 mg Diclofenac Sodium IP 50 mg	1 ml	M/s Fast Pharma Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	30.58
20	4(20)	Empagliflozin, Sitagliptin and Metformin Hydrochloride Extended Release Tablets	Each film coated bilayer tablet contains: Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s USV Pvt. Ltd.	14.88
21	4(21)	Myo-Inositol, D-Chiro Inositol and Vitamin D3 Powder	Each 5g Sachet contains: Vitamin D3 (Stabilized form) 1000 IU Myo-Inositol IP 2000 mg D-Chiro Inositol 50mg	1 gm	M/s Safetab Life Science/ M/s Mankind Pharma Ltd.	9.52
22	4(22)	Norethisterone Acetate Controlled Release Tablets	Each Film Coated Controlled Release Tablet contains: Norethisterone Acetate BP 15 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Zorvia Healthcare Ltd.	20.11
23	4(23)	Norethisterone Acetate Controlled Release Tablets	Each Film Coated Controlled Release Tablet contains: Norethisterone Acetate BP 10 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Zorvia Healthcare Ltd.	18.40
24	4(24)	Paracetamol, Phenylephrine Hydrochloride and	Each uncoated tablet contains: Paracetamol IP 500mg	1 Tablet	M/s East African (India) Overseas/ M/s Macleods Pharmaceuticals Ltd.	5.15

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
		Chlorpheniramine Maleate Tablets	Phenylephrine Hydrochloride IP 10mg Chlorpheniramine Maleate IP 2mg			
25	4(25)	Sitagliptin, Glimepiride and Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Alkem Wellness Ltd.	11.91
26	4(26)	Sitagliptin, Glimepiride and Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Alkem Wellness Ltd.	10.39
27	4(27)	Teneligliptin and Dapagliflozin Tablets	Each Film Coated Tablet Contains: Teneligliptin Hydrobromide Hydrate IP Eq. to Teneligliptin 20 mg Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Wellness Ltd.	10.17
28	4(28)	Trypsin-Chymotrypsin With Paracetamol and Aceclofenac Tablets	Each film coated tablet contains: 50,000 Armour Units Enzymatic Activity Supplied by a Purified Concentrate which has Specific Trypsin & Chymotrypsin Activity in a Ratio of Approximately Six to One (As enteric coated granules) Paracetamol IP 325 mg Aceclofenac IP 100 mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd./ M/s Troikaa Pharmaceuticals Ltd.	13.02
29	4(29)	Vildagliptin and Metformin Hydrochloride Tablets	Each film coated tablet contains: Vildagliptin IP 50 mg Metformin Hydrochloride IP 1000 mg	1 Tablet	M/s Ved Lifesavers (P) Ltd./ M/s Alkem Wellness Ltd.	9.79
30	4(30)	Tacrolimus Prolonged Release Capsules	Each hard gelatin capsule contains: Tacrolimus IP 3 mg	1 Capsule	M/s Zydus Lifesciences Ltd.	127.00 (Note-2)

Note-1: M/s. Intas Pharmaceuticals Ltd. filed a representation dated 30.04.2026 against the draft working sheet uploaded on website on 21.04.2026 stating that inadvertently due to a clerical error, the pack size in Form-I was wrongly mentioned as 15 ml instead of the actual 5 ml pack of "CALCITAS D3 NANO SHOTS", and requested approval of the existing MRP of

Rs.78.28 per 5 ml bottle (Rs. 15.66 per ml). Accordingly, revised draft working sheet with claim price of Rs.14.91 per ml exclusive of taxes was uploaded on website on 12.05.2026.

Note-2: The Authority recalled that the matter was deferred in 145th meeting held on 30.04.2026 based on representation dated 31.03.2026 with a direction to refer the matter to the Multidisciplinary Committee of Experts for examination of the issues raised. Subsequently, the applicant company vide letter dated 06.05.2026 revised its claim price to Rs. 127.00 per capsule exclusive of GST. The Authority deliberated upon the matter and decided to approve retail price of Rs.127.00 per capsule being lower than the worked-out price.

5. Agenda item no. 5: Request by M/s Fresenius Kabi India Private Limited for inclusion of 'Eurohead' Bottle packaging for Ringer Lactate in NPPA notification no. 1584(E) dated 25.03.2026.

5.1 The Authority deliberated upon the request of M/s. Fresenius Kabi India Private Limited seeking inclusion/clarification of "Eurohead bottle" packaging under NPPA Notification No. 1584(E) dated 25.03.2026 relating to Ringer Lactate Injection.

5.2 The Authority noted that the Multidisciplinary Committee, in its 6th meeting held on 15.01.2019, had examined and recommended separate ceiling prices for Ringer Lactate Injection in "Non-Glass with special features" category after demonstration of the products by the company. The records available in the file, including the application dated 14.01.2019 and PPT submitted by the company, indicate that both packaging types, namely "Freeflex bags" and "Eurohead bottle", were demonstrated before the Committee.

5.3 The Authority also observed that while notifying the ceiling price vide S.O. 960(E) dated 03.03.2020 and subsequent WPI notifications issued for the years 2020, 2021, 2022 and 2023, the specific packaging type was not mentioned. However, from the WPI notification issued for the year 2024 onwards, product names were specifically incorporated against the company and only "Freeflex bags" was mentioned. The same position continued in the notifications issued for the years 2025 and 2026.

5.4 In view of the above facts, the Authority decided that "Eurohead bottle" packaging for M/s. Fresenius Kabi India Private Limited may also be included under Notification No. 1584(E) dated 25.03.2026 for Ringer Lactate Injection.

6. Agenda item no. 6: Status of implementation of Review cases

6.1 Noted.

7. Agenda item no. 7: Revision of ceiling prices of Benzathine 'Benzylpenicillin Powder for injection 6 lacs units' based on review order.

7.1 The Authority noted that Department of Pharmaceuticals (DoP) has issued Review Order no. 31015/06/2024-Pricing (E-26460) dated 20.03.2026 in respect of scheduled formulation 'Benzylpenicillin Powder for injection 6 lacs units' stating that contention of the applicant company regarding incorrect fixation of ceiling price of scheduled formulation is accepted and referred the matter back to NPPA for recalculation of the ceiling price of the subject formulation as per the extant provisions of DPCO, 2013.

7.2 The Authority noted that M/s Pfizer Limited had filed a review application against S.O. No. 938(E) dated 28.02.2024 stating that the PTR considered for its brand 'Penidure LA 6 Injection' was incorrect. The applicant also enclosed Form-II filed on 05.04.2023 along with Review Petition claiming price revision as per WPI w.e.f. April-2023.

7.3 In view of the above Review Order, the facts submitted by the company have been examined and accordingly the revised draft working sheet incorporating the corrected PTR of 'Penidure LA 6 Injection' was uploaded on NPPA website on 07.05.2026. The Authority noted that no representation has been received against the revised draft working sheet uploaded on the website. The details of prevailing ceiling price and revised ceiling price are shown in Table below:

Particulars	Ceiling Price notified (in Rs.)	Revised Ceiling Price based on review order (In Rs.)
Fixed in February 2024	11.69	13.10
Add: WPI @0.00551%	0.00	0.00
w.e.f. 01.04.2024	11.69	13.10
Add: WPI @1.74028%	0.20	0.23
w.e.f. 01.04.2025	11.89	13.33
Add: WPI @0.64956%	0.08	0.09
w.e.f. 01.04.2026	11.97	13.42

7.4 Accordingly, the Authority approved the revised ceiling price of 'Benzathine Benzylpenicillin Powder for Injection 6 lac units' at Rs.13.42 per vial inclusive of WPI revision of April 2026.

8. Agenda item no. 8 Ceiling price fixation of IV Fluids formulations under NLEM,2022.

8.1 The Authority noted that the ceiling prices of IV Fluids formulations have undergone revisions since 2014 on account of issues relating to pack-size wise pricing, categorization of packaging materials, admissibility of special features, and directions issued by the Department of Pharmaceuticals through various review orders. The Authority further noted that methodologies presently being followed for different IV Fluids formulations are different.

8.2 The Authority further noted that over the years, formulations having "special features" packaging have evolved into a significant market segment with substantial market turnover.

8.3 After detailed deliberations, the Authority observed that the matter may be examined by the subject experts. Accordingly, the Authority decided that the matter may be referred to the Multi-Disciplinary Committee (MDC) for further examination regarding methodology for ceiling prices fixation of IV Fluids including packs with special features.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.


(Sai Ahladini Panda)
Member Secretary